More than 95 percent of patients eventually succumb to drug-resistant GIST, underscoring the importance of starting patients on the most effective available drug
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.